SCHEMBL4056022

SCHEMBL4056022

C(=C/c1nc2ncc(-c3cccs3)cc2[nH]1)\c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.44
KDM4E B2RXH2 5/20 0.44
ALDH1A1 P00352 5/20 0.44
HPGD P15428 4/20 0.44
RAB9A P51151 4/20 0.44
SMN1; SMN2 Q16637 4/20 0.44
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
PKM P14618 2/20 0.44
HSP90AA1 P07900 1/20 0.44
MAPT P10636 5/20 0.40
MAPK1 P28482 2/20 0.40
CYP1A2 P05177 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP2D6 P10635 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
TRPV1 Q8NER1 1/20 0.39
ATM Q13315 1/20 0.38
CHEK1 O14757 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4056027 1.00 NPC1 (0.44) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4056642 0.83 NPC1 (0.51) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4056638 0.83 NPC1 (0.51) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL13608067 0.81 KDM4E (0.44) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4055727 0.79 NPC1 (0.55) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4055724 0.79 NPC1 (0.55) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4060105 0.77 NPC1 (0.45) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4060113 0.77 NPC1 (0.45) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4059729 0.76 NPC1 (0.44) NPC1KDM4EALDH1A1HPGDRAB9A
SCHEMBL4059720 0.76 NPC1 (0.44) NPC1KDM4EALDH1A1HPGDRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NPC1 4740/4885KDM4E 496/4885ALDH1A1 3683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.